Inventor · disambiguated record
David J. King
Also filed as: KING DAVID · KING DAVID J · KING DAVID JOHN
63 granted patents·46 pending applications·1,514 citations·filing 1995–2025
99Inventor score
Files withANAPTYSBIO INC28MEDAREX INC13ATYR PHARMA INC6LIFE TECHNOLOGIES CORP6MOMENTA PHARMACEUTICALS INC5
Top patents by PatentIndex Score
109 records- 0198US7498302B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2005·Granted Mar 3, 2009·123 cites·32 claims
- 0298US6989452B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2002·Granted Jan 24, 2006·284 cites·21 claims
- 0397US9315861B2Enhanced ligation reactionsLIFE TECHNOLOGIES CORP·Filed 2012·Granted Apr 19, 2016·63 cites·14 claims
- 0497US8034959B2Methods of treating cancer with an antibody-drug conjugateMEDAREX INC·Filed 2009·Granted Oct 11, 2011·37 cites·19 claims
- 0596US10738117B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Aug 11, 2020·10 cites·9 claims
- 0696US8865875B2Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensionsLIU JIE·Filed 2008·Granted Oct 21, 2014·41 cites·11 claims
- 0796US6511663B1Tri- and tetra-valent monospecific antigen-binding proteinsCELLTECH R&D LTD·Filed 2000·Granted Jan 28, 2003·172 cites·8 claims
- 0895US9815897B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2014·Granted Nov 14, 2017·24 cites·44 claims
- 0994US10676526B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2016·Granted Jun 9, 2020·9 cites·19 claims
- 1094US9765388B2Enhanced ligation reactionsLIFE TECHNOLOGIES CORP·Filed 2016·Granted Sep 19, 2017·5 cites·8 claims
- 1193US10526410B2Antibodies directed against interleukin 36 receptor (IL-36R)ANAPTYSBIO INC·Filed 2016·Granted Jan 7, 2020·7 cites·28 claims
- 1293US8124738B2Human monoclonal antibodies to CD70TERRET JONATHAN ALEXANDER·Filed 2006·Granted Feb 28, 2012·102 cites·22 claims
- 1392US8097703B2CD19 antibodies and their usesRAO-NAIK CHETANA·Filed 2006·Granted Jan 17, 2012·71 cites·20 claims
- 1492US7012135B2Biological productsCELLTECH CHIROSCIENCE LTD·Filed 2001·Granted Mar 14, 2006·63 cites·3 claims
- 1592US6423493B1Combinatorial selection of oligonucleotide aptamersUNIV TEXAS·Filed 1999·Granted Jul 23, 2002·85 cites·21 claims
- 1692US5864019AMultivalent antigen-binding proteinsCELLTECH LTD·Filed 1995·Granted Jan 26, 1999·136 cites·21 claims
- 1791US10508149B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2016·Granted Dec 17, 2019·7 cites·25 claims
- 1891US6307026B1Humanized antibodies directed against A33 antigenCELLTECH LTD·Filed 1997·Granted Oct 23, 2001·83 cites·19 claims
- 1990US11753472B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2021·Granted Sep 12, 2023·2 cites·19 claims
- 2090US9133269B2Humanized antibodies directed against complement protein C5ANAPTYSBIO INC·Filed 2013·Granted Sep 15, 2015·20 cites·34 claims
- 2190US8481683B2Human antibodies that bind CD22 and uses thereofKING DAVID JOHN·Filed 2007·Granted Jul 9, 2013·31 cites·20 claims
- 2289US11807687B2Therapeutic compositions comprising anti-NRP2 antibodiesATYR PHARMA INC·Filed 2020·Granted Nov 7, 2023·2 cites·13 claims
- 2389US10093969B2Enhanced ligation reactionsLIFE TECHNOLOGIES CORP·Filed 2017·Granted Oct 9, 2018·2 cites·19 claims
- 2488US11130814B2Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)ANAPTYSBIO INC·Filed 2019·Granted Sep 28, 2021·2 cites·27 claims
- 2588US10059764B2Antibodies directed against interleukin-33 (IL-33) and methods of making and usingANAPTYSBIO INC·Filed 2015·Granted Aug 28, 2018·6 cites·28 claims
- 2687US12129303B2Anti-interleukin-11 receptor subunit α (IL-11Rα) antibodiesLASSEN THERAPEUTICS 1 INC·Filed 2024·Granted Oct 29, 2024·1 cites·16 claims
- 2787US11345751B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2017·Granted May 31, 2022·4 cites·40 claims
- 2887US11155624B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Oct 26, 2021·4 cites·14 claims
- 2987US7741449B2Anti-interferon alpha antibodiesMEDAREX INC·Filed 2004·Granted Jun 22, 2010·19 cites·16 claims
- 3087US7402662B2Antibody molecules specific to human tumor necrosis factor alphaUCB PHARMA SA·Filed 2006·Granted Jul 22, 2008·12 cites·2 claims
- 3186US12065495B2Compositions and methods comprising anti-NRP2 antibodiesATYR PHARMA INC·Filed 2022·Granted Aug 20, 2024·1 cites·15 claims
- 3286US9499632B2Human antibodies that bind CD22 and uses thereofSQUIBB & SONS LLC·Filed 2013·Granted Nov 22, 2016·8 cites·42 claims
- 3385US11352427B2Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2019·Granted Jun 7, 2022·2 cites·10 claims
- 3484US8025882B2Interferon alpha antibodies and their usesMEDAREX INC·Filed 2009·Granted Sep 27, 2011·4 cites·12 claims
- 3584US2024294631A1Antibodies directed against interleukin-33 (il-33)ANAPTYSBIO INC·Filed 2024·Application pending·0 cites
- 3683US11732047B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·1 cites·26 claims
- 3782US12365738B2Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibodyLASSEN THERAPEUTICS INC·Filed 2024·Granted Jul 22, 2025·0 cites·16 claims
- 3882US2023331843A1Antibodies Directed Against Programmed Death-1(PD-1)ANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 3981US11505610B2Compositions and methods comprising anti-NRP2 antibodiesATYR PHARMA INC·Filed 2019·Granted Nov 22, 2022·3 cites·12 claims
- 4081US10836820B2Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)ANAPTYSBIO INC·Filed 2018·Granted Nov 17, 2020·1 cites·8 claims
- 4181US7977464B2Antibody molecules specific to human tumour necrosis factor alphaUCB PHARMA SA·Filed 2008·Granted Jul 12, 2011·3 cites·22 claims
- 4280US12410253B2Compositions comprising anti-NRP2 antibodiesATYR PHARMA INC·Filed 2023·Granted Sep 9, 2025·0 cites·15 claims
- 4379US8828393B2Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonistPICKFORD LESLEY B·Filed 2011·Granted Sep 9, 2014·6 cites·16 claims
- 4479US7781569B2Antibodies to treat cancerUNIV MASSACHUSETTS·Filed 2006·Granted Aug 24, 2010·2 cites·26 claims
- 4579US2024002930A1Enzymatic ligation of nucleic acidsLIFE TECHNOLOGIES CORP·Filed 2023·Application pending·0 cites
- 4679US2025368746A1Method of treating diseases or conditions by administering an anti-interleukin-11 receptor subunit alpha (il-11ra) antibodyLASSEN THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4778US7939076B2Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonistMEDAREX INC·Filed 2004·Granted May 10, 2011·9 cites·16 claims
- 4878US7935338B2Antibodies to treat cancerUNIV MASSACHUSETTS·Filed 2002·Granted May 3, 2011·3 cites·50 claims
- 4978US7888484B2Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)MEDAREX INC·Filed 2009·Granted Feb 15, 2011·2 cites·5 claims
- 5078US7619070B2Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)MEDAREX INC·Filed 2004·Granted Nov 17, 2009·8 cites·17 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David J. King files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →